Supporter News
Navigating Immune Challenges in CLL
Infection Prevention and Management We recognise that receiving a CLL diagnosis is scary and finding accessible information on CLL can be challenging. The Advocacy Working Group of the CLL IC Task Force, spearheaded by CLLAN, is committed to supporting people living with CLL and immune challenges as well as their family and carers to understand…
Leadership Update at Lymphoma Coaltion
Leadership Transition Lorna Warwick to retire in December 2026 After eight years of leadership, Lymphoma Coalition’s CEO, Lorna Warwick, will be retiring later this year, in December 2026. This milestone will mark a significant milestone for the organisation. Lorna has played a central role in shaping Lymphoma Coalition into a robust, data-driven organisation. The strategy,…
Global MPN Clinical Trials 101: Understanding MPN Research Around the World
Global MPN Clinical Trials 101: Understanding MPN Research Around the World MPN United Webinar Series – March 27, 2026 This session provides an introductory overview of the global MPN clinical trial landscape, including available treatments, the need for international research, and the challenges many countries face in running MPN studies. The webinar also highlights how…
Save the date for the 7th International CLL Horizons conference!
We’re heading to Barcelona 16-18 October. See you there! The CLL Advocates Network Steering Committee is asking you to Save The Date for CLL Horizons 2026 Barcelona, Spain, on 16-18 October 2026.This will be the third year in a row for the Horizons, growing in size and momentum among the advocate community. Following a tremendous event last year in…
FOLC MARCH 2025
Latest News Across LC The 2026 Global Patient Survey on Lymphomas & CLL is Closing Today After ten weeks of incredible momentum, the 2026 Global Patient Survey on Lymphomas & CLL will formally conclude at 9:00 AM BST on April 1. Over 7,900 responses have already been submitted from patients and care partners around the…
How Doctors Talk to Patients Affects Their Quality of Life — New Global Leukemia Study
A landmark international study involving more than 2,260 leukaemia patients from 64 countries has found that the quality of communication between clinicians and patients is significantly associated with patients’ quality of life (QoL) — and that depression and social isolation are among the most powerful predictors of poor wellbeing. What the Study Did Researchers used…
Variances In Patient Experiences With Shared Decision-Making By Treatment In Patients With LBCL: Analysis Of Lymphoma Coalition’s 2024 Global Patient Survey On Lymphomas And CLL
TopicsAll ResearchCommunication & Decision-MakingDoctor–Patient CommunicationShared Decision-MakingAccess to CareAgeBarriers to TreatmentCOVIDPsychosocial & Quality of LifePsychosocialSurvivorshipQuality of LifeTreatment & Side EffectsCAR-TClinical TrialsFatigueSide EffectsTreatmentSubtype-SpecificCLLHodgkin LymphomaRelapse/RefractoryHealth Literacy EBMT 2026 Annual Meeting Poster FV 1Download Variances In Patient Experiences With Shared Decision-Making By Treatment In Patients With LBCL: Analysis Of Lymphoma Coalition’s 2024 Global Patient Survey On Lymphomas And CLL…
Testing
Different tests are used to diagnose lymphoma, to know how much lymphoma is in the body (called ‘staging’), to help doctors assess how well different treatments might work, and to measure if treatments are working. /* widget: Icon Bullets */ #uc_uc_material_bullets_elementor_765c4b8 *{ -webkit-box-sizing: border-box; -moz-box-sizing: border-box; box-sizing: border-box; } #uc_uc_material_bullets_elementor_765c4b8 .ue-icon-wrapper{ display: flex; } #uc_uc_material_bullets_elementor_765c4b8…
Website Disclaimer
CLL Advocates Network Effective March 16, 2026 The information provided by Network name (“we,” “our,” or “us”) on this website is for general informational and educational purposes only. By using this website, you agree to the terms outlined in this Disclaimer. 1. No Medical Advice – The content on this website, including text, graphics, articles,…
PACIFICA-Study
This study is testing how well pacritinib works compared to other standard treatments in people with a type of blood cancer called myelofibrosis (MF) who also have very low platelet counts. MF can occur on its own (PMF) or after other MPN (PPV-MF or PET-MF). Who Can Join People with moderate to high-risk MF based on a scoring system called DIPSS.…
